跳至主要内容
临床试验/NCT01307553
NCT01307553Unknown不适用

OVER AND UNDER/ANEUGRAFT PERICARDIUM COVERED STENT Long Term Follow Up Registry

ITGI Medical2 个研究点 分布在 2 个国家目标入组 75 人开始时间: 2010年9月最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
75
试验地点
2
主要终点
MACE (Major Adverse Clinical Events)

研究概览

简要总结

The purpose of this study is to track the clinical safety and effectiveness of the Pericardium Covered Stent in "real world" use.

详细描述

This is a multi-center registry of 75 patients treated with the Over and Under/Aneugraft Pericardium Covered Stent (PCS) (IGTI, Israel). The registry will involve the collection of demographic, clinical, and angiographic data on the treated patient population, including in-hospital, 30 day, 6-month, 1 year, 2 years and 3 years clinical follow-up data.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient is older than 18 years
  • Patient must be available for follow-up
  • Patient must be fully informed, provided with the patient information sheet and sign the Informed Consent Form prior to the procedure.
  • The lesion to be treated should be suitable for treatment with a PCS in that:
  • A. A suitable length and diameter PCS should be available
  • B. For SVG disease a single or multiple PCS may be used
  • C. For native coronary artery aneurysms the operator should be confident that the aneurysm may be excluded by the implantation of a single PCS

排除标准

  • Significant co-morbidity precluding clinical follow-up.
  • Pregnancy; pregnancy test negative in women with child bearing potential
  • Acute ST-elevation myocardial infarction within the preceding 48 hours
  • Previous stent implantation in the target vessel
  • Left main coronary artery disease
  • Contra-indication to dual anti-platelet therapy.
  • Planned surgery which will lead to discontinuation of antiplatelet therapy
  • Thrombocytopenia (<100,000/mm3)
  • Ejection fraction <30%.
  • Renal failure (creatinine >180 µmol/L [2 mg/dL])
  • Prior brachytherapy
  • Recipient of heart transplant
  • Acute infections

结局指标

主要结局

MACE (Major Adverse Clinical Events)

时间窗: 6 months

次要结局

  • MACE(30 days, 1 Year, 2 Years, 3 Years)
  • Hospital readmission due to cardiac reason.(30 days, 6 months. 1 Year, 2 Years, 3 Years)

研究者

发起方
ITGI Medical
申办方类型
Industry

研究点 (2)

Loading locations...

相似试验

Over and Under/Aneugraft Pericardium Covered Stent... | 临床试验